Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-23T05:29:07.387Z Has data issue: false hasContentIssue false
  • English
  • Français

Choreoathetosis, an unusual presentation of serotonin syndrome

Published online by Cambridge University Press:  13 June 2014

Phillip Hodnett ,
Radhakrishnan Renganathan ,
Patricia Fitzgerald  and
Gaivin Roderick
Phillip Hodnett
Affiliation:
Cork University Hospital, Wilton, Cork, Ireland
Radhakrishnan Renganathan
Affiliation:
Cork University Hospital, Wilton, Cork, Ireland
Patricia Fitzgerald
Affiliation:
Cork University Hospital, Wilton, Cork, Ireland
Gaivin Roderick
Affiliation:
Cork University Hospital, Wilton, Cork, Ireland
Get access Rights & Permissions [Opens in a new window]

Abstract

We describe a 63 year old male with serotonin syndrome, presenting with choreoathetosis. Differentiating this syndrome from neuroleptic malignant syndrome remains a challenge. It is important to be aware of drugs that can potentially precipitate this syndrome.

Keywords

Serotonin syndromeChoreoatheosisDiagnostic criteria.
Type
Case Report
Information
Irish Journal of Psychological Medicine , Volume 23 , Issue 2 , June 2006 , pp. 80 - 81
Copyright
Copyright © Cambridge University Press 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Oates, JA, Sjoerdsma, A. Neurologic effects of tryptophan in patients receiving a monoamine oxidase inhibitor. Neurology 1960; 10: 107–110.CrossRefGoogle ScholarPubMed
2.Sternbach, HThe serotonin syndrome. Am J Psychiatry 1991; 148: 705–13.Google ScholarPubMed
3.Radomski, JW, Dursun, SM. An exploratory approach to the serotonin syndrome; Med Hypotheses 2000; 55: 218–24.CrossRefGoogle Scholar
4.Hilton, SE, Maradit, H. Serotonin syndrome and drug combinations. Eur Arch Psychiatry Clin Neuroscience 1997; 247: 113–19.CrossRefGoogle ScholarPubMed
5.Stalh, SM. Essential psychopharmacology. 2nd ed. Cambridge: 2000.Google Scholar
6.Nierenberg, DW, Semprebon, M.The central nervous system serotonin syndrome. Clin Pharmacol Ther 1993; 53: 84–88.CrossRefGoogle ScholarPubMed
7.Mason, PJ, Morris, VA. Serotonin syndrome. Medicine 2000; 79: 201–9.CrossRefGoogle ScholarPubMed
8.Gillman, PK. Serotonin syndrome. History and risk. Fundam Clin Pharmacol 1998; 12:482–91.CrossRefGoogle ScholarPubMed
9.LoCurto, MJ. The serotonin syndrome. Emerg Med Clin North Am 1997; 15: 665–758.CrossRefGoogle ScholarPubMed
10.Trinidade, E, Menon, D.Adverse effects associated with selective serotonin reuptake inhibitors and antidepressants. CMAJ 1998; 159: 1245–52.Google Scholar
11.Sanders-Bush, E, Conn, JP. Neurochemistry of serotonin neuronal systems: Psychopharmacology, 3rd generation of progress. 1987; 95–1038.Google Scholar
12.Carbone, JR. The neuroleptic malignant and serotonin syndromes. Emerg Med Clin North Am 2000; 18:317–25.CrossRefGoogle ScholarPubMed
13.Levenson, JLNeuroleptic malignant syndrome. Am J Psychiatry 1985; 142; 1137–45.Google ScholarPubMed
14.Gillman, PK. The serotonin syndrome and its treatment. J Psychopharmacol 1999; 13: 100–9.CrossRefGoogle ScholarPubMed
15.Kolecki, P.Isolated venlafaxine induced serotonin syndrome. J Emerg Med 1997; 15:491–93.CrossRefGoogle ScholarPubMed
16.Lane, R, Baldwin, P.Selective serotonin reuptake inhibitor induced serotonin syndrome: Review J Clin Psychoparmacol 1997;17: 208–21.CrossRefGoogle ScholarPubMed
17.Graudins, A, Stearmin, A.Treatment of the serotonin syndrome with cyproheptadine. J Emerg Med 1998;16:615–19.CrossRefGoogle ScholarPubMed
18.Martin, TG. Serotonin syndrome. Ann Emerg Med 1996; 28: 520–26.CrossRefGoogle ScholarPubMed
19.Lappin, RI, Auchincloss. Treatment of the serotonin syndrome with cyproheptadine. The New England Journal Of Medicine 1994; 331 : 1021–22.CrossRefGoogle ScholarPubMed
20.Mills, KC. Serotonin syndrome, a clinical update. Crit Care Clin 1997; 13: 763–83.CrossRefGoogle ScholarPubMed